Page 34 - Read Online

Padh. J Cancer Metastasis Treat 2018;4:52 I http://dx.doi.org/10.20517/2394-4722.2018.51 Page 5 of 5

8. Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global
and microgeographic scales. Pharmacogenet Genomics 2009;19:170-9.
9. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice.
Clin Pharmacol Ther 2012;92:467-75.
10. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature 2015;526:343-50.
11. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero MH, Carson AR, Chen W, Cho EK, Dallaire S,
Freeman JL, González JR, Gratacòs M, Huang J, Kalaitzopoulos D, Komura D, MacDonald JR, Marshall CR, Mei R, Montgomery L,
Nishimura K, Okamura K, Shen F, Somerville MJ, Tchinda J, Valsesia A, Woodwark C, Yang F, Zhang J, Zerjal T, Zhang J, Armengol L,
Conrad DF, Estivill X, Tyler-Smith C, Carter NP, Aburatani H, Lee C, Jones KW, Scherer SW, Hurles ME. Global variation in copy number
in the human genome. Nature 2006;444:444-54.
12. Almal SH, Padh H. Implications of gene copy-number variation in health and diseases. J Hum Genet 2012;57:6-13.
13. Robert J, Le Morvan V, Giovannetti E, Peters GJ; PAMM Group of EORTC. On the use of pharmacogenetics in cancer treatment and
clinical trials. Eur J Cancer 2014;50:2532-43.